A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass effect and high bioavailability, which provides an important means to deliver therapeutics directly to lung lesions. Sta...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanobiotechnology 2022-03, Vol.20 (1), p.101-101, Article 101
Main Authors: He, Siqin, Gui, Jiajia, Xiong, Kun, Chen, Meiwan, Gao, Huile, Fu, Yao
Format: Article
Language:English
Subjects:
Administration, Inhalation
Analysis
Bioavailability
Care and treatment
Diagnosis
Dosage and administration
Drug delivery
Drug Delivery Systems
Drugs
Humans
Lung
Lung diseases
Methods
Pneumonia
Pulmonary function tests
Pulmonary infectious disease
Respiratory agents
Review
Risk factors
Targeting
Therapeutic strategies
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass effect and high bioavailability, which provides an important means to deliver therapeutics directly to lung lesions. Starting from the structural characteristics of the lungs and the biological barriers for achieving efficient delivery, we aim to review literatures in the past decade regarding the pulmonary delivery strategies used to treat infectious lung diseases. Hopefully, this review article offers new insights into the future development of therapeutic strategies against pulmonary infectious diseases from a delivery point of view.
ISSN:1477-3155
1477-3155
DOI:10.1186/s12951-022-01307-x